세리티닙(Ceritinib) 시장 규모, 점유율, 성장 분석 : 유형별, 치료 용도별, 용도별, 최종사용자별, 유통 채널별, 지역별 - 산업 예측(2026-2033년)

Global Ceritinib Market size was valued at USD 423.1 Million in 2024 and is poised to grow from USD 452.29 Million in 2025 to USD 771.33 Million by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The global ceritinib market is primarily fueled by the necessity to address ALK rearranged non-small cell lung cancer, leveraging targeted inhibitors that significantly improve survival outcomes. Developed by Novartis, ceritinib stands out in the precision medicine landscape by translating genetic data into effective treatments, particularly for patients resistant to crizotinib. The market has shifted from chemotherapy reliance to biomarker-driven care, supported by increasing diagnostic adoption and regulatory approvals, which enhance prescribing confidence, especially in crizotinib-resistant cohorts. A major trend is the rise in molecular testing in conjunction with guideline implementation, broadening the ALK-positive patient base. The prevalence of ALK testing facilitates earlier ceritinib use, particularly for patients with central nervous system metastases, while clearer reimbursement models and combined therapy trials further propel market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ceritinib market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ceritinib Market Segments Analysis

Global ceritinib market is segmented by type, therapeutic use, application, end user, distribution channel and region. Based on type, the market is segmented into 50 capsules/box, 90 capsules/box and 150 capsules/box. Based on therapeutic use, the market is segmented into first-line treatment, second-line treatment and refractory cases. Based on application, the market is segmented into hospital, clinic, pharmacy and others. Based on end user, the market is segmented into public healthcare, private healthcare and research institutes. Based on distribution channel, the market is segmented into direct sales, pharmacy chains and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ceritinib Market

One of the key market drivers for the global Ceritinib market is the rising incidence of ALK-positive non-small cell lung cancer (NSCLC), which has led to an increased demand for targeted therapies. As awareness and diagnosis of this genetic mutation improve, more patients are being identified who can benefit from Ceritinib, a potent ALK inhibitor. Additionally, ongoing research and clinical trials exploring the efficacy of Ceritinib in combination with other treatment modalities are further propelling its uptake in clinical settings. The growing emphasis on personalized medicine will likely continue to enhance its market presence in oncology.

Restraints in the Global Ceritinib Market

A significant market restraint for the global ceritinib market is the high cost associated with the drug, which can limit accessibility for patients requiring treatment for advanced lung cancer. This financial barrier is compounded by the stringent regulatory processes and the necessity for health insurance coverage, which varies widely across regions. Furthermore, the availability of alternative therapies may lead healthcare providers to opt for less expensive treatments, further constraining ceritinib's market penetration. Additionally, ongoing challenges related to patient awareness and education about ceritinib may result in underutilization, ultimately impacting its market growth potential.

Market Trends of the Global Ceritinib Market

The global ceritinib market is experiencing a notable upward trend characterized by the expanding adoption of targeted therapies in oncology. As biomarkers and companion diagnostics enhance patient selection, oncologists are increasingly integrating ceritinib into treatment protocols, fostering precision medicine. Improved clinician familiarity is driving greater confidence in ceritinib's application, particularly in earlier treatment stages and smaller patient populations. Furthermore, synergistic collaborations between pharmaceutical and diagnostic companies are bolstering its market presence. Ongoing clinical trials and educational initiatives are pivotal in establishing ceritinib's efficacy, positioning it as a cornerstone in personalized treatment strategies for lung cancer, thus solidifying its role in global oncology.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Ceritinib Market Size by Type & CAGR (2026-2033)

• Market Overview
• 50 Capsules/Box
• 90 Capsules/Box
• 150 Capsules/Box

Global Ceritinib Market Size by Therapeutic Use & CAGR (2026-2033)

• Market Overview
• First-line Treatment
• Second-line Treatment
• Refractory Cases

Global Ceritinib Market Size by Application & CAGR (2026-2033)

• Market Overview
• Hospital
• Clinic
• Pharmacy
• Others

Global Ceritinib Market Size by End User & CAGR (2026-2033)

• Market Overview
• Public Healthcare
• Private Healthcare
• Research Institutes

Global Ceritinib Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Sales
• Pharmacy Chains
• Online Pharmacies

Global Ceritinib Market Size & CAGR (2026-2033)

• North America (Type, Therapeutic Use, Application, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Therapeutic Use, Application, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Therapeutic Use, Application, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Therapeutic Use, Application, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Therapeutic Use, Application, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations